Atossa Therapeutics, Inc. (FRA:YAG2)

Atossa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	14.42	13.5	14.04	12.61	11.31	8
Research & Development	18.43	14.12	17.33	15.08	9.21	6.61
Operating Expenses	32.86	27.62	31.38	27.69	20.52	14.61
Operating Income	-32.86	-27.62	-31.38	-27.69	-20.52	-14.61
Interest & Investment Income	2.77	4.05	4.34	0.88	0.01	-
Other Non Operating Income (Expenses)	-0.1	-0.22	-0.07	-0.15	-0.09	-3.22
EBT Excluding Unusual Items	-30.18	-23.79	-27.1	-26.96	-20.61	-17.83
Gain (Loss) on Sale of Investments	-	-1.71	-2.99	-	-	-
Pretax Income	-30.18	-25.5	-30.09	-26.96	-20.61	-17.83
Earnings From Continuing Operations	-30.18	-25.5	-30.09	-26.96	-20.61	-17.83
Net Income	-30.18	-25.5	-30.09	-26.96	-20.61	-17.83
Preferred Dividends & Other Adjustments	-	-	-	-	-	4.5
Net Income to Common	-30.18	-25.5	-30.09	-26.96	-20.61	-22.33
Shares Outstanding (Basic)	129	126	126	127	117	11
Shares Outstanding (Diluted)	129	126	126	127	117	11
Shares Change (YoY)	2.39%	-0.18%	-0.43%	8.27%	934.13%	33.09%
EPS (Basic)	-0.23	-0.20	-0.24	-0.21	-0.18	-1.97
EPS (Diluted)	-0.23	-0.20	-0.24	-0.21	-0.18	-1.97
Free Cash Flow	-26.29	-21.05	-20.96	-20.79	-16.48	-11.58
Free Cash Flow Per Share	-0.20	-0.17	-0.17	-0.16	-0.14	-1.02
EBITDA	-32.84	-27.6	-31.35	-27.68	-20.5	-14.56
D&A For EBITDA	0.02	0.02	0.02	0.01	0.02	0.05
EBIT	-32.86	-27.62	-31.38	-27.69	-20.52	-14.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.